Provided by Tiger Trade Technology Pte. Ltd.

SKB BIO

467.400
-7.000-1.48%
Volume:244.72K
Turnover:113.60M
Market Cap:111.71B
PE:-241.37
High:473.800
Open:465.200
Low:459.800
Close:474.400
52wk High:581.000
52wk Low:339.600
Shares:239.00M
HK Float Shares:177.00M
Volume Ratio:0.88
T/O Rate:0.14%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.936
ROE:2.92%
ROA:0.03%
PB:17.91
PE(LYR):-241.37
PS:45.82

Loading ...

Kelun-Biotech says Phase III trial tests sac-TMT plus osimertinib in first-line EGFR-mutant NSCLC

Reuters
·
Jun 22

Movement Alert|Kelun-Biotech Falls 3.7% in Regular Trading, Biotech Sector Broadly Under Pressure

Market Focus
·
Jun 22

Industrial Securities Initiates Coverage on SKB BIO with "Overweight" Rating Following Key ASCO Lung Cancer Data Release

Stock News
·
Jun 18

Movement Alert|Kelun-Biotech Rises 3.03% in Regular Trading, RMB 703 Million Settlement Payment from Yilian Bio Continues to Catalyze

Market Focus
·
Jun 15

Innovative Drug Stocks See Broad Gains as Sector's Outbound Licensing Activity Remains Robust, Supported by Policy Tailwinds and Commercialization Progress

Stock News
·
Jun 12

Sichuan Kelun-Biotech Receives Nearly 603 Million Yuan From MediLink

MT Newswires Live
·
Jun 12

Movement Alert|Kelun-Biotech Rises 7.35% in Regular Trading, Receives RMB 7.03 Billion Settlement Payment from Yilian Biopharmaceutical

Market Focus
·
Jun 12

SKB BIO Receives Settlement Payment from Yilian Biopharma

Stock News
·
Jun 12

Sichuan Kelun-Biotech Biopharmaceutical Co - Receives RMB602.5 Mln From Medilink Therapeutics for Out-Licensing of Yl201

THOMSON REUTERS
·
Jun 12

Movement Alert|Kelun-Biotech Falls 3.34% in Regular Trading, Biotech Sector Broadly Weakens Amid Ongoing Chairman Sell-Off Pressure

Market Focus
·
Jun 11

Hong Kong Stocks Show Movement: Super-Long-Acting Anti-TSLP Antibody Phase II Trial Completes First Dosing; HBM Holdings-B and SKB BIO Both Surge Over 5% During Session

Stock News
·
Jun 10

Movement Alert|Kelun-Biotech Rises 3.25% in Regular Trading, Multiple Brokerages Maintain Buy Ratings as ASCO Data Continues to Catalyze

Market Focus
·
Jun 10

Kelun-Biotech says partner Windward Bio doses first patients in Phase 2 COPD trial of SKB378/WIN378

Reuters
·
Jun 09

Kelun-Biotech Partner Windward Bio Announces First Patients Dosed in Phase 2 Sirius Copd Study of Skb378/Win378

THOMSON REUTERS
·
Jun 09

A Look At Sichuan Kelun-Biotech Biopharmaceutical’s (SEHK:6990) Valuation After Positive 2026 ASCO Lung Cancer Data

Simply Wall St.
·
Jun 08

Movement Alert|Kelun-Biotech Falls 3.15% in Regular Trading, Chairman Continuous Share Sales Combined with Widening Losses Sustain Selling Pressure

Market Focus
·
Jun 08

Domestic Innovative Drugs Initiate Paradigm Shift in First-Line NSCLC Treatment, Says Orient Securities

Stock News
·
Jun 08

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Is Down 14.8% After ASCO NSCLC Data Spotlight - Has The Bull Case Changed?

Simply Wall St.
·
Jun 06

Shares of SKB BIO Surge Over 7% on Milestone Breakthrough in OptiTROP-Lung05 Study

Stock News
·
Jun 05

Movement Alert|Kelun-Biotech Rises 3.54% in Regular Trading, Buyback Plan and ASCO Clinical Data Provide Dual Catalysts

Market Focus
·
Jun 05